ASSESSMENT OF TOBACCO SMOKE-MEDIATED ATHEROSCLEROSIS IN MOUSE MODEL

C. Gary Gairola, Ph. D. University of Kentucky Lexington, KY

- 1. Models of human atherosclerosis
- 2. Description of model used in our studies
- **3. End points**
- 4. Measurement of atherosclerotic lesion
- 5. Smoke studies
- 6. Strengths and Weaknesses of the model
- 7. Information needed for reduced risk assessment

ANIMAL MODELS OF ATHEROSCLEROSIS

Two types-Diet-induced -Genetically manipulated Lipid or lipoprotein disorders Develop Hyperlipidemia Current Usage--genetically manipulated mice

Most extensively used models: apolipoprotein E or LDL-receptor- deficient mice



• Regular mouse chow

• High saturated fat/cholesterol diet 21% fat, 0.5-1.5% cholesterol

MOUSE AORTA



Lesion Size Determination: Aortic Root



INTIMAL LESION AREA MEASUREMENT

- Aorta cleaned, opened and pinned
- Lesions traced under dissecting microscope
- Images captured with a digital camera for analysis by appropriate programs
- Planar measurements of the area

Quantification of Atherosclerotic Lesions En Face



ANIMAL MODEL USED IN OUR STUDIES

C57Bl-apolipoprotein E-knock out mice LDLreceptor-deficient mice Commercially available from Jackson Laboratories, Maine

CHARACTERSTICS

- ApoE-deficiency induces hypercholestrolemia because the LDL/VLDL are not cleared.
- Animals develop atherosclerotic lesions on the intimal surface of the aorta which are formed all through the aortic tree.
- Time course dependent on diet.

END POINTS

- lesion area
- plasma cholesterol
- aortic tissue cholesterol
- aortic constriction and relaxation ?

SMOKE STUDIES

EXPERIMENTAL

- ApoE-deficient mice -- Two Groups-Sham controls (SH) and Smoke-exposed (SM)
- Exposures are in a whole-body exposure chamber to sidestream smoke from 1R4F cigarettes.
- Exposures are for 4 hrs/day, 5 days /week.
- Animals were sacrificed and plasma lipids and aorta examined.

University of Kentucky Research Cigarettes



WHOLE-BODY SMOKE EXPOSURE SYSTEM



WHOLE-BODY CHAMBER FOR EXPOSURE OF RODENTS TO CIGARETTE SMOKE

Total Particulate Matter 32±4 mg/m³



Body Weights of ApoE^{-/-} Mice



Lung Ethoxyresorufin-O-deethylase Activity



CYP1A1-PROTEIN LEVELS IN SMOKE-EXPOSED ApoE^{-/-} MICE LUNGS



URINARY COTININE

CONTROL vs SMOKE apoE-/- mice



PLASMA CHOLESTEROL IN ApoE^{-/-} MICE

Sham vs Smoke-exposed



LIPIDS (mg/dl)

DISTRIBUTION OF LIPOPROTIEN-CHOLESTEROL IN PLASMA ApoE-/-Mice: Control and Smoke-Exposed



En Face Comparison of Aortic Lesions apoE^{-/-} Study



Control Mouse Aorta

Smoke-Exposed Mouse Aorta

TOTAL AORIC INTIMAL AREA COVERED BY LESIONS

Sham vs Smoke-exposed ApoE^{-/-} Mice



ATHEROSCLEROTIC LESION AREA Sham vs Smoke-exposed ApoE -/- Mice



AORTIC TISSUE CHOLESTEROL CONTENT

Sham vs Smoke-exposed



Control #11 Aorta 100x Accurate Macrophage 1:1000



Smoker #5_Aorta 100x Accurate Macrophage 1:100



Control #11 Aorta 100x No Primary Ab



Smoker #5 Aorta 100x No Primarv Al



CIGARETTE MODIFICATION

Plasma Cholesterol of ApoE^{-/-} Mice



Atherosclerotic Lesions in ApoE^{-/-} Mice



Free Cholesterol in ApoE^{-/-} Mice Vessels



Total Cholesterol in ApoE^{-/-} Mice Vessels



DIETARY INTERVENTION

DIETARY CoQ10 INTERVENTION



CHOLESTEROL DISTRIBUTION



Dietary CoQ10 and Atherosclerosis



NOSE-ONLY vs WHOLE-BODY

Diet and Cholesterol Distribution

C57BL Mice-Standard and High Cholesterol Diet



STANDARD

HIGH CHOLESTEROL



SMOKE EXPOSURE AND ATHEROSCLEROSIS C57Bl Mice-High Cholesterol Diet



SMOKE EXPOSURE AND ATHEROSCLEROSIS C57Bl Mice-High Cholesterol Diet



STRENGTHS

- Relevant disease end point
- Quantitative
- Reproducible
- Large data base available

WEAKNESSES

- Thrombosis
- Sites of lesion formation
- Labor-intensive and expensive
- Dose-response not yet established

WHAT IS NEEDED TO STANDARDIZE AND EVALUATE THE ASSAY?

- Dose response --smoke particulates conc.vs disease
 -urinary/plasma cotinine vs disease
- Longer exposures --plaque composition and rupture
- Standard vs Western Diet
- Plaque area vs vessel cholesterol
- Whole vs gas phase smoke

Important points Committee needed to be addressed

- Description of the model
- Animal disease endpoints and relevance to human physiology and disease
- Method of exposure and relevance to human exposures
- Reproducibility
- Practicality (sample size/expense/study duration)
- Dose-response
- Significance of observed change in biological response
- Uncertainties and shortcomings
- Overall validity for evaluating claims of reduced risk
- How are doses selected?
- How many animals need to be used?
- How should data be reported/ normalized?

Saline

Control ApoE-/-



Ang II









































